Delving into the Latest Updates on Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive HPCs(NCI) with Synapse

Overview

Basic Info

Drug Type

Gene therapy

Synonyms

Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells(NCI)

Target-

Action-

Mechanism

Gene transference(Gene transference)

Therapeutic Areas

NeoplasmsImmune System DiseasesInfectious Diseases+ [3]

Active Indication

Burkitt LymphomaHIV InfectionsMantle-Cell Lymphoma+ [9]

Inactive Indication-

Originator Organization

National Cancer Institute

Active Organization

City of Hope National Medical Center

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

This phase I/II trial studies the side effects and best dose of gene therapy in treating patients with human immunodeficiency virus (HIV)-related lymphoma that did not respond to therapy or came back after an original response receiving stem cell transplant. In gene therapy, small stretches of deoxyribonucleic acid (DNA) called "anti-HIV genes" are introduced into the stem cells in the laboratory to make the gene therapy product used in this study. The type of anti-HIV genes and therapy in this study may make the patient's immune cells more resistant to HIV-1 and prevent new immune cells from getting infected with HIV-1.

Start Date23 Jun 2016

Sponsor / Collaborator

California Institute for Regenerative Medicine

[+1]

NCT01961063

/ Active, not recruitingPhase 1IIT

Safety and Feasibility of Gene Transfer After Frontline Chemotherapy for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated With a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs

This pilot clinical trial studies gene therapy after frontline chemotherapy in treating patients with acquired immune deficiency syndrome (AIDS)-related non-Hodgkin lymphoma (NHL). Placing genes for anti-human immunodeficiency virus (HIV) ribonucleic acid (RNA) into stem/progenitor cells may make the body build an immune response to AIDS. Giving the chemotherapy drug busulfan before gene therapy can help gene-modified cells engraft and work better.

Start Date31 Dec 2015

Sponsor / Collaborator

City of Hope National Medical Center

NCT02337985

/ Active, not recruitingPhase 1IIT

Safety and Feasibility of Stem Cell Gene Transfer Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated With a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs

This pilot clinical trial studies gene therapy following combination chemotherapy in treating patients with acquired immune deficiency syndrome (AIDS)-related non-Hodgkin lymphoma. Placing genes that have been shown in the laboratory to inhibit the growth and spread of the immunodeficiency virus (HIV) into the patient's peripheral blood stem cells may improve the body's ability to fight HIV. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving gene therapy after combination chemotherapy may improve the body's ability to fight HIV and AIDS-related non-Hodgkin lymphoma.

Start Date20 Nov 2015

Sponsor / Collaborator

City of Hope National Medical Center

[+1]

100 Clinical Results associated with Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive HPCs(NCI)

Login to view more data

100 Translational Medicine associated with Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive HPCs(NCI)

Login to view more data

100 Patents (Medical) associated with Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive HPCs(NCI)

Login to view more data

100 Deals associated with Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive HPCs(NCI)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Burkitt Lymphoma	Phase 2	United States	-	23 Jun 2016
HIV Infections	Phase 2	United States	-	23 Jun 2016
Mantle-Cell Lymphoma	Phase 2	United States	-	23 Jun 2016
Peripheral T-Cell Lymphoma	Phase 2	United States	-	23 Jun 2016
Plasmablastic Lymphoma	Phase 2	United States	-	23 Jun 2016
Recurrent Follicular Lymphoma	Phase 2	United States	-	23 Jun 2016
Recurrent Hodgkin Lymphoma	Phase 2	United States	-	23 Jun 2016
Recurrent Non-Hodgkin Lymphoma	Phase 2	United States	-	23 Jun 2016
Acquired Immunodeficiency Syndrome	Phase 1	United States	City of Hope National Medical Center	20 Nov 2015
AIDS-Related Diffuse Large Cell Lymphoma	Phase 1	United States	City of Hope National Medical Center	20 Nov 2015

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02797470 (CTgov)	Phase 1/2	Recurrent Follicular Lymphoma \| Mantle-Cell Lymphoma \| Plasmablastic Lymphoma ... View more	11	BEAM+TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells+etoposide+carmustine+Melphalan+Cytarabine (Treatment (Anti-HIV Gene Transduced CD34+ Cells): 1:0 Ratio)	ivfejuvxrg(irsagkevhq) = lzsgmjbhnx qnuhoivovx (mfpdkvamwf, hchgaswgtj - fhxeohrxez) View more	-	20 Jul 2023
				etoposide+carmustine+melphalan+cytarabine (Treatment (Anti-HIV Gene Transduced CD34+ Cells): 1:1 Ratio)	ivfejuvxrg(irsagkevhq) = clzzfmfecq qnuhoivovx (mfpdkvamwf, gfgiwuzctr - qhbcdnkqoy) View more